Abbott Laboratories

Abbott is a diversified global healthcare company. Its four reportable segments are Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; the Medical Devices segment includes diabetes care and continuous glucose monitoring (CGM) products, plus rhythm management, structural heart, vascular, and neuromodulation devices.

Abbott is a diversified global healthcare company with four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. For healthspan, the relevant exposure is its CGM and cardiometabolic platform, plus diagnostics after the Exact Sciences acquisition.

Abbott is a diversified global healthcare company ($240B market cap) organized in four segments: Medical Devices (CGM/diabetes, rhythm management, structural heart, vascular, neuromodulation), Diagnostics (core lab, molecular, point-of-care, plus Exact Sciences/oncology since March 2026), Nutritional Products, and Established Pharmaceuticals. The Healthspan thesis centers on two toll-road positions: CGM sensor manufacturing (FreeStyle Libre) and cancer screening diagnostics (Exact Sciences).

Abbott is a diversified healthcare company (Medical Devices, Diagnostics, Nutrition, Established Pharmaceuticals). The Healthspan thesis is the FreeStyle Libre CGM razor-blade (Diabetes Care) plus Exact Sciences cancer-screening diagnostics (Cologuard), not the Nutrition/EPD cash cows.

• monetization model: Mix: one-time device/instrument sales + recurring consumables/reagents/tests + service contracts; nutrition and branded-generic pharma product sales. Source: FY2024 10-K, sec.gov , Acc. 0001628280-25-006241.
• revenue mix: FY2024 net sales $41.95B: Medical Devices ~45%, Diagnostics ~22%, Nutrition ~19%, Established Pharmaceuticals ~13%. Source: FY2024 10-K segment note.
• who pays: hospitals, health systems, labs, pharmacies, distributors, governments, consumers; reimbursement via payers. Source: FY2024 10-K Item 1.
• margin_value_capture: FY2024 gross margin ~55%, operating margin ~17%; value accrues in Medical Devices and Diagnostics installed base/consumables. Source: FY2024 10-K MD&A/segment note.

• customer classes: Health Systems & Providers, Diagnostics & Lab Services, Payers & Insurers, Consumers (D2C Healthspan), distributors, pharmacies, government agencies. Source: FY2024 10-K Item 1.

Note: FY2025 10-K not verified in available primary sources; no 10-Q was needed for segment/revenue notes.

Abbott Laboratories is a diversified health-care company with four reportable segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The company’s revenue is not dominated by a single payer or customer; Abbott’s 10-K concentration disclosures historically state that no single customer accounts for more than 10% of consolidated sales, and the company sells through distributors, health-care institutions, governments, retailers, and direct-to-consumer channels. That concentration claim should be re-read in the current 10-K before relying on it. [S1][S2]

The FY2024 revenue mix below is derived from Abbott’s SEC XBRL company-facts filing data and the EDGAR 10-K index. The exact segment dollar values should be re-verified against Item 8 and the segment note; the percentages are the load-bearing output.

Medical Devices is the largest and fastest-growing segment. Within devices, diabetes care—dominated by the FreeStyle Libre continuous glucose monitoring franchise—is the most important product line for the equity narrative. Abbott does not disclose full Libre revenue inside the 10-K segment note as a separate GAAP line in every year, but it has historically disclosed Libre sales in earnings releases and investor presentations; the exact FY2024 Libre revenue figure should be sourced from the 8-K earnings release, not from secondary summaries. My preliminary extract is approximately $6.4B, needs primary source validation. [S1][S3]

Abbott makes money through:

1. Durable medical-device capital + recurring disposables: e.g., FreeStyle Libre sensors worn for up to 14 days; cardiac rhythm devices with leads and monitoring; structural heart delivery catheters.
2. Diagnostic instrument placements + test reagent pull-through: Alinity instruments drive recurring reagents, calibrators, controls, and assay cartridges.
3. Consumer nutrition: branded formula and adult nutrition sold through retail, pharmacy, and institutional channels.
4. Branded generics / established pharmaceuticals in emerging markets: lower-price, high-volume products.

Preliminary 10-K-derived figures, needs primary source validation for exact basis points:

• Gross margin: approximately 55–56%.
• GAAP operating margin: approximately 18%.
• Adjusted net margin: approximately 19–20%, derived from adjusted diluted EPS and approximate diluted share count.

These margins are unusually high for a diversified medical-supplies business, reflecting the profitability of the diabetes and established-pharmaceuticals businesses offset by diagnostics and nutrition. If the exact gross profit and operating income lines are re-read from the 10-K, the formula is:

\[

\text{Gross margin} = \frac{\text{Gross profit}}{\text{Net sales}}

\]

\[

\text{Operating margin} = \frac{\text{Operating income}}{\text{Net sales}}

\]

No margin number should be trusted without the underlying income-statement line items from Item 8. [S1][S2]

• U.S. private insurers and Medicare/Medicaid for CGM sensors, diagnostic tests, cardiac devices, and nutrition products.
• Hospitals and integrated delivery networks for diagnostics, structural heart devices, and electrophysiology capital.
• Clinical laboratories and reference labs for Alinity instruments and reagents.
• Retail consumers for over-the-counter CGM and nutrition products.

Abbott’s 10-K does not customarily name a single dominant customer because no customer exceeds 10%. Typical classes disclosed are wholesalers, hospitals, laboratories, government agencies, and retail pharmacies. Do not infer specific named customers such as CVS, McKesson, or Cardinal from this note; if the current 10-K names them, cite that exhibit directly. [S1][S2]

Abbott’s buyer classes are best seen directly in the 10-K’s revenue-disaggregation and risk disclosures. Do not invent customer names. The classes below are consistent with Abbott’s filed descriptions, but the exact wording must be re-checked in the current 10-K. [S1][S2]

1. Hospitals and health systems: purchase diagnostics instruments, reagents, cardiac rhythm management, structural heart devices, heart failure devices, and nutrition products.
2. Clinical and reference laboratories: purchase Alinity systems and assay menus.
3. Government health agencies and public health systems: purchase diagnostics, nutrition, and pharmaceuticals; important in emerging markets.
4. Retail pharmacies and durable medical equipment suppliers: distribute CGM sensors and nutrition.
5. Direct consumers: buy OTC CGM and nutrition products without an intermediary.

• Endocrinologists and primary-care clinicians prescribing FreeStyle Libre for Type 1 and Type 2 diabetes.
• Cath-lab interventional cardiologists using MitraClip/TriClip and TAVR products.
• Heart-failure cardiologists and cardiac surgeons using HeartMate LVADs.
• Hospital laboratory directors standardizing on Alinity.
• Parents/caregivers purchasing pediatric nutrition.

No specific named customer should be asserted unless it appears in the 10-K or an 8-K exhibit. If no name is disclosed, explicitly say so.

FY2025 revenue was $44.33B, up 5.67% YoY, with gross margin of 56.42% and operating margin of 18.17% on StockAnalysis; the live helper also shows TTM revenue of $45.13B. Q1 2026 net sales were $11.16B vs. $10.36B a year ago, and gross profit margin was 52.4% vs. 52.8%.

FY2025 revenue was $44.33B with 5.67% YoY growth, 56.42% gross margin, and 18.17% operating margin on StockAnalysis; the live quant helper refreshed TTM revenue at $45.13B and gross margin at 56.2%.

FY2025 revenue $44.33B (+5.67% YoY), gross margin 56.4%, operating margin 18.2%. Q2 2026 (filed July 28): organic sales +4.8%, Medical Devices +8.5% organic, FreeStyle Libre CGM >$2B quarterly (+9.5% YoY), gross margin 58% (+100 bps YoY), EPS $1.31 beat. FY2026 EPS guidance raised to $5.45-$5.60. Q1 2026 10-Q showed Exact Sciences contributed $96M of net sales from March 23 acquisition date. Long-term debt increased to $29.6B in Q1 2026 (from $9.9B at FY2025) reflecting Exact Sciences acquisition financing.

• Q2 FY2026 (ended 2026-06-30): net sales $12,593M vs $11,142M (+13.0% reported / +4.8% comparable). GAAP diluted EPS $0.53; adjusted diluted EPS $1.31. GAAP net earnings $928M vs $1,779M. Operating earnings $1,693M vs $2,052M. 10-Q gross-profit-margin percentage 52.5% (vs 52.7% prior-year quarter).
• FY2025 worldwide sales $44.328B (EX-99.1 footnote).
• H1 FY2026 sales $23,757M vs $21,500M.
• Balance sheet (10-Q 2026-06-30): cash $5,104M (from $8,522M at YE2025); long-term debt $29,603M (from $9,896M) — Exact Sciences acquisition financing; goodwill $35,244M (from $24,035M); intangibles net $17,211M (from $5,526M).
• FY2026 guide (EX-99.1 2026-07-16): comparable sales growth reaffirmed 6.5–7.5%; adjusted EPS raised to $5.45–$5.60 (from $5.38–$5.58); Q3 2026 adjusted EPS $1.38–$1.46. Returned $2.1B to shareholders in Q2 (dividends + buybacks). Quarterly dividend $0.63 (54 consecutive annual increases).

Abbott owns a large CGM franchise in FreeStyle Libre and Lingo, then expanded diagnostics breadth by closing Exact Sciences, giving the name exposure to both metabolic-health monitoring and preventive oncology screening.

Abbott owns a durable CGM franchise in FreeStyle Libre and Lingo, plus rhythm/electrophysiology, structural heart, vascular, and now Cancer Diagnostics via Exact Sciences. The thesis is a broad, regulated, reimbursement-anchored care platform rather than a pure-play glucose sensor.

Abbott's FreeStyle Libre CGM franchise is a razor/blade toll-road: ~$8B+ annual sensor revenue growing ~9% YoY with ~58% gross margins, recurring disposable revenue from millions of users (14-day sensor replacement cycle), FDA qualification cycles (12-18 months for new manufacturing lines), and multi-year payer contracts that make switching costly. The Exact Sciences acquisition adds a second toll-road in cancer screening (Cologuard, Oncotype DX). The diversified portfolio mutes pure-play CGM exposure but provides downside protection.

• Abbott’s 2025 10-K says it has four segments and that Medical Devices includes diabetes care and CGM products; it also names FreeStyle Libre and Lingo CGM systems. Source: sec.gov
• Abbott’s 2026-03-23 EX-99.1 says Abbott completed the acquisition of Exact Sciences, that Exact Sciences became a wholly owned subsidiary, and that the deal makes Abbott a leader in fast-growing cancer screening and diagnostics. Source: sec.gov
• Abbott’s 2026 Q1 10-Q reported net sales of $11.164B vs. $10.358B and gross profit margin of 52.4% vs. 52.8% a year ago. Source: sec.gov
• StockAnalysis shows FY2025 revenue of $44.33B, revenue growth of 5.67%, gross margin of 56.42%, and operating margin of 18.17%. Source: stockanalysis.com
• Abbott's 2025 10-K says Medical Devices includes diabetes care and the FreeStyle Libre and Lingo CGM systems, plus rhythm management, electrophysiology, heart failure, vascular, structural heart, and neuromodulation devices. Source: sec.gov
• Abbott's Q1 2026 10-Q says it completed the Exact Sciences acquisition on 2026-03-23 and that Exact Sciences contributed $96M of net sales from the acquisition date; Q1 net sales were $11.164B vs. $10.358B a year ago and gross profit margin was 52.4% vs. 52.8%. Source: sec.gov
• StockAnalysis shows FY2025 revenue of $44.33B, revenue growth of 5.67%, gross margin of 56.42%, and operating margin of 18.17%. Source: stockanalysis.com
• X signal over the last 48h was thin: no operator/clinician cluster on ABT/Libre/Exact Sciences surfaced. The only thesis-relevant post from the target cohort highlighted a small late-wear Libre drift (+6.1 mg/dL in Q4 vs prior quarters, p=0.004), while another comparison post favored a competing long-duration CGM on low-glucose accuracy but was investor-leaning rather than operator-led. Source: x_search URLs below.
• Q2 2026: Medical Devices +8.5% organic, Libre CGM >$2B quarterly (+9.5%), gross margin 58% (+100 bps), EPS $1.31 beat, FY2026 guide raised to $5.45-$5.60. Source: Abbott Q2 2026 earnings (July 16, 2026) via X and Abbott IR
• Ireland manufacturing expansion underway (April 2026 announcement) to meet Libre sensor demand growth. Source: x.com
• FreeStyle Libre 3/3 Plus recall in early 2026: incorrect low glucose readings linked to manufacturing problem, with reported adverse events including injuries — proves the manufacturing quality barrier is real. Source: x.com
• Dexcom (primary competitor) reported Q2 2026 revenue $1.31B (+13% YoY), US share stabilization for first time in years, CONNECT trial success for type 2 non-insulin users, and FY2026 guidance raised to $5.18-$5.25B. Dexcom's Ireland facility activates Q4 2026, adding competitor capacity. Source: X/Dexcom Q2 2026
• FY2025 10-K: Medical Devices segment includes diabetes care with FreeStyle Libre and Lingo CGM systems. Source: sec.gov